Schering/ICN Intron A/Rebetol
Executive Summary
NDA 20-903 for interferon alpha-2b/Ribivirin combination product for treatment of chronic hepatitis C will be discussed by FDA's Antiviral Drugs Advisory Committee on May 4. The meeting begins at 8:30 a.m...